SCHEMBL4040276

SCHEMBL4040276

CCCc1cc(Nc2nc(Cl)ncc2Cl)n[nH]1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FGFR1 P11362 4/20 0.46
IGF1R P08069 4/20 0.46
KDR P35968 3/20 0.46
INSR P06213 1/20 0.45
NTRK1 P04629 5/20 0.44
JAK2 O60674 3/20 0.44
AURKA O14965 2/20 0.44
JAK3 P52333 2/20 0.44
PLK4 O00444 2/20 0.44
PAK4 O96013 2/20 0.44
STK10 O94804 1/20 0.44
RET P07949 1/20 0.44
FER P16591 1/20 0.44
CSNK2A2 P19784 1/20 0.44
JAK1 P23458 1/20 0.44
TYK2 P29597 1/20 0.44
FLT3 P36888 1/20 0.44
STAT3 P40763 1/20 0.44
STAT5A P42229 1/20 0.44
CDK3 Q00526 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1770945 0.89 FGFR1 (0.46) FGFR1IGF1RKDRNTRK1JAK2
SCHEMBL4034896 0.87 IGF1R (0.60) FGFR1IGF1RKDRINSRJAK2
SCHEMBL218642 0.82 MEN1 (0.62) FGFR1IGF1RKDRINSRNTRK1
SCHEMBL4076750 0.80 IGF1R (0.40) FGFR1IGF1RKDRNTRK1JAK2
SCHEMBL3856477 0.79 GRK6 (0.45) FGFR1IGF1RKDRNTRK1JAK2
SCHEMBL4073779 0.79 IGF1R (0.42) FGFR1IGF1RKDRNTRK1JAK2
SCHEMBL2120951 0.78 NTRK1 (0.58) FGFR1IGF1RKDRNTRK1JAK2
SCHEMBL4010728 0.77 FGFR1 (0.44) FGFR1IGF1RKDRINSRAURKA
SCHEMBL4031791 0.77 IGF1R (0.79) FGFR1IGF1RKDRINSRNTRK1
SCHEMBL4037330 0.77 IGF1R (0.67) FGFR1IGF1RKDRINSRNTRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090131463-A1 NOVEL COMPOUNDS ASTRAZENECA AB (SE) 2009-05-21 US disclosed
EP-1456182-B1 PYRIMIDINE DERIVATIVES AS MODULATORS OF INSULINE-LIKE GROWTH FACTOR-1 RECEPTOR (IGF-I) ASTRAZENECA AB (SE) 2009-03-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131463-A1 NOVEL COMPOUNDS C1R, TBXA2R, F12 FGFR1 1251/4885IGF1R 1655/4885KDR 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.